ALLO

1.42

2.07% -0.03

Handel nachbörslich: 1.39 -0.03 -2.11%

Allogene Therapeutics Inc (ALLO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.45

Offen:

$1.41

24-Stunden-Volumen:

2.18M

Relative Volume:

0.42

Marktkapitalisierung:

$310.69M

Einnahmen:

$95,000

Nettoeinkommen (Verlust:

$-327.27M

KGV:

-0.6698

EPS:

-2.12

Netto-Cashflow:

$-239.25M

1W Leistung:

-0.70%

1M Leistung:

-12.35%

6M Leistung:

-49.29%

1J Leistung:

-59.08%

1-Tages-Spanne:

$1.39

$1.49

1-Wochen-Bereich:

$1.375

$1.53

52-Wochen-Spanne:

$1.23

$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Firmenname

Allogene Therapeutics Inc

Sektor

Healthcare (1155)

Branche

Biotechnology (677)

Telefon

(650) 457-2700

Adresse

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Mitarbeiter

361

Twitter

@AllogeneTx

Nächster Verdiensttermin

2025-03-04

Neueste SEC-Einreichungen

ALLO's Discussions on Twitter

Vergleichen Sie ALLO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALLO Allogene Therapeutics Inc	1.42	310.69M	95,000	-327.27M	-239.25M	-2.12
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-14	Hochstufung	Citizens JMP	Mkt Perform → Mkt Outperform
2024-08-08	Fortgesetzt	Oppenheimer	Outperform
2024-05-31	Eingeleitet	Piper Sandler	Overweight
2024-01-05	Herabstufung	Guggenheim	Buy → Neutral
2024-01-05	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-08	Eingeleitet	Citigroup	Buy
2023-06-26	Fortgesetzt	Oppenheimer	Outperform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2023-01-24	Hochstufung	JP Morgan	Neutral → Overweight
2023-01-06	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-12-12	Herabstufung	BofA Securities	Buy → Underperform
2022-08-10	Herabstufung	Raymond James	Outperform → Mkt Perform
2022-07-15	Hochstufung	Goldman	Neutral → Buy
2022-06-03	Eingeleitet	Robert W. Baird	Neutral
2022-02-28	Bestätigt	B. Riley Securities	Buy
2021-10-20	Eingeleitet	Cowen	Outperform
2021-10-08	Herabstufung	Goldman	Buy → Neutral
2021-10-08	Herabstufung	Stifel	Buy → Hold
2021-09-23	Hochstufung	Raymond James	Mkt Perform → Outperform
2021-06-21	Fortgesetzt	Jefferies	Buy
2021-05-20	Hochstufung	Truist	Hold → Buy
2021-05-14	Eingeleitet	B. Riley Securities	Buy
2021-01-26	Hochstufung	Stifel	Hold → Buy
2020-12-10	Fortgesetzt	H.C. Wainwright	Buy
2020-11-24	Eingeleitet	BofA Securities	Buy
2020-10-23	Eingeleitet	RBC Capital Mkts	Outperform
2020-06-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-05-29	Bestätigt	H.C. Wainwright	Buy
2020-05-19	Hochstufung	ROTH Capital	Neutral → Buy
2020-05-15	Hochstufung	Guggenheim	Neutral → Buy
2020-05-14	Bestätigt	H.C. Wainwright	Buy
2020-05-14	Herabstufung	SunTrust	Buy → Hold
2020-04-13	Eingeleitet	SunTrust	Buy
2020-03-13	Eingeleitet	H.C. Wainwright	Buy
2020-03-05	Eingeleitet	Stifel	Hold
2020-02-24	Eingeleitet	Berenberg	Hold
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-11-04	Eingeleitet	Canaccord Genuity	Buy
2019-08-09	Eingeleitet	BTIG Research	Buy
2019-06-05	Eingeleitet	ROTH Capital	Neutral
2019-05-31	Eingeleitet	Guggenheim	Neutral
2019-05-23	Eingeleitet	Stifel	Hold
2019-03-29	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten

Apr 10, 2025

Allogene received FDA Fast-track statuses for its dual CAR-Therapy - MSN

Apr 10, 2025

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Apr 10, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 08, 2025

FDA Grants Three Fast Track Tags To Allogene's Autoimmune Disease Drug - Barchart.com

Apr 08, 2025

Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy By Investing.com - Investing.com South Africa

Apr 07, 2025

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Apr 07, 2025

Allogene's ALLO-329 Granted Three FDA Fast Track Designations - Nasdaq

Apr 07, 2025

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases - marketscreener.com

Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 - MarketScreener

Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - The Manila Times

Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy - Investing.com

Apr 07, 2025

Groundbreaking Triple FDA Fast Track: Allogene's New CAR T Targets Multiple Autoimmune Diseases - Stock Titan

Apr 07, 2025

Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline - Investing.com

Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025

Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025

Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025

Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025

Mar 14, 2025